Novartis' radioligand therapy Lutathera could soon face generic competition

Novartis' radioligand therapies are shipped in green lead-shielded canisters (Novartis) April 23, 2026 01:49 PM EDTUpdated April 23, 11:06 PM PharmaIn FocusManufacturing No­var­tis built a big busi­ness around de­liv­er­ing ra­dioac­tive can­cer treat­ments. Can a gener­ic com­pete? Nicole DeFeudis Senior Reporter The ra­di­oli­gand field is on the cusp of a ma­jor com­pet­i­tive mo­ment, as a ri­val looks to bring the first gener­ic to a mar­ket that’s … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER